Comprehensive molecular profiling broadens treatment options for breast cancer patients

被引：30

作者：

Kawaji, Hitomi ^{[1
]}

Kubo, Makoto ^{[1
]}

Yamashita, Nami ^{[2
]}

Yamamoto, Hidetaka ^{[3
]}

Kai, Masaya ^{[1
]}

Kajihara, Atsuko ^{[4
]}

Yamada, Mai ^{[1
]}

Kurata, Kanako ^{[1
]}

Kaneshiro, Kazuhisa ^{[1
]}

Harada, Yurina ^{[1
]}

Hayashi, Saori ^{[1
]}

Shimazaki, Akiko ^{[1
]}

Mori, Hitomi ^{[1
]}

Akiyoshi, Sayuri ^{[2
]}

Oki, Eiji ^{[2
]}

Oda, Yoshinao ^{[3
]}

Baba, Eishi ^{[5
]}

Mori, Masaki ^{[2
]}

Nakamura, Masafumi ^{[1
]}

机构：

[1] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Fukuoka, Japan

[2] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka, Japan

[3] Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Fukuoka, Japan

[4] Chugai Pharmaceut Co Ltd, Fdn Med Unit, Fdn Med Business Dept, Tokyo, Japan

[5] Kyushu Univ, Grad Sch Med Sci, Dept Oncol & Social Med, Fukuoka, Japan

来源：

CANCER MEDICINE | 2021年 / 10卷 / 02期

基金：

日本学术振兴会;

关键词：

breast cancer; ERBB2; next generation sequencing; precision oncology; tumor mutational burden; BRCA MUTATION CARRIERS; SOMATIC MUTATIONS; HER2; SURVIVAL; OVARIAN; ASSAY; TRASTUZUMAB; VALIDATION; OLAPARIB; IMPACT;

D O I：

10.1002/cam4.3619

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Precision oncology with next generation sequencing (NGS) using tumor tissue with or without blood has begun in Japan. Tumor molecular profiling tests are available, including the OncoGuide (TM) NCC Oncopanel System and FoundationOne(R) CDx (F1CDx). Our purpose was to identify potentially actionable genetic alterations in breast cancer with this comprehensive tumor profiling test. We enrolled 115 patients with pathologically diagnosed advanced or metastatic breast cancer. Comprehensive tumor genomic profiling, microsatellite instability, and tumor mutational burden (TMB) were determined using F1CDx. Testing was successful in 109/115 cases (94.8%). Clinically actionable alterations were identified in 76% of advanced breast cancer patients. The most frequent short variants were in TP53 (48.6%), PIK3CA (38.5%), GATA3 (11.0%), PTEN (11.0%), and BRCA1 (10.1%), and structural variants were in ERBB2 (24.8%), MYC (21.1%), RAD21 (21.1%), CCND1 (11.9%), FGF19 (10.1%), and PTEN (10.1%). Regarding human epidermal growth factor receptor (HER)2 status, 106/109 samples (97.2%) were concordant between F1CDx and HER2 testing with immunohistochemistry/fluorescence in situ hybridization. However, ERBB2 amplification was newly detected in four samples and ERBB2 mutations were detected in five HER2-negative breast cancer samples. Oncogenic BRCA mutations were found in three samples with F1CDx among 27 germline testing-negative samples. The mean TMB in all samples was 6.28 mut/Mb and tended to be higher in luminal B and triple-negative breast cancer (mean = 8.1 and 5.9 mut/Mb, respectively) compared with other subtypes. In conclusion, we established a system for precision oncology and obtained preliminary data with NGS as the first step. The information in this clinical sequencing panel will help guide the development of new treatments for breast cancer patients.

引用

页码：529 / 539

页数：11

共 42 条

[1] Signatures of mutational processes in human cancer [J].

Alexandrov, Ludmil B. ;

Nik-Zainal, Serena ;

Wedge, David C. ;

Aparicio, Samuel A. J. R. ;

Behjati, Sam ;

Biankin, Andrew V. ;

Bignell, Graham R. ;

Bolli, Niccolo ;

Borg, Ake ;

Borresen-Dale, Anne-Lise ;

Boyault, Sandrine ;

Burkhardt, Birgit ;

Butler, Adam P. ;

Caldas, Carlos ;

Davies, Helen R. ;

Desmedt, Christine ;

Eils, Roland ;

Eyfjord, Jorunn Erla ;

Foekens, John A. ;

Greaves, Mel ;

Hosoda, Fumie ;

Hutter, Barbara ;

Ilicic, Tomislav ;

Imbeaud, Sandrine ;

Imielinsk, Marcin ;

Jaeger, Natalie ;

Jones, David T. W. ;

Jones, David ;

Knappskog, Stian ;

Kool, Marcel ;

Lakhani, Sunil R. ;

Lopez-Otin, Carlos ;

Martin, Sancha ;

Munshi, Nikhil C. ;

Nakamura, Hiromi ;

Northcott, Paul A. ;

Pajic, Marina ;

Papaemmanuil, Elli ;

Paradiso, Angelo ;

Pearson, John V. ;

Puente, Xose S. ;

Raine, Keiran ;

Ramakrishna, Manasa ;

Richardson, Andrea L. ;

Richter, Julia ;

Rosenstiel, Philip ;

Schlesner, Matthias ;

Schumacher, Ton N. ;

Span, Paul N. ;

Teague, Jon W. .

NATURE, 2013, 500 (7463) :415-+

[2] Response of an ERBB2-Mutated Inflammatory Breast Carcinoma to Human Epidermal Growth Factor Receptor 2-Targeted Therapy [J].

Ali, Siraj M. ;

Alpaugh, R. Katherine ;

Downing, Sean R. ;

Stephens, Philip J. ;

Yu, Jian Q. ;

Wu, Hong ;

Buell, Jamie K. ;

Miller, Vincent A. ;

Lipson, Doron ;

Palmer, Gary A. ;

Ross, Jeffrey S. ;

Cristofanilli, Massimo .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (25) :E88-E91

[3]

[Anonymous], FDA APPR ALP MET BRE

[4]

Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]

[5] HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor [J].

Ben-Baruch, Noa Efrat ;

Bose, Ron ;

Kavuri, Shyam M. ;

Ma, Cynthia X. ;

Ellis, Matthew J. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (09) :1061-1064

[6] Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer [J].

Bose, Ron ;

Kavuri, Shyam M. ;

Searleman, Adam C. ;

Shen, Wei ;

Shen, Dong ;

Koboldt, Daniel C. ;

Monsey, John ;

Goel, Nicholas ;

Aronson, Adam B. ;

Li, Shunqiang ;

Ma, Cynthia X. ;

Ding, Li ;

Mardis, Elaine R. ;

Ellis, Matthew J. .

CANCER DISCOVERY, 2013, 3 (02) :224-237

[7] Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology [J].

Cheng, Donavan T. ;

Mitchell, Talia N. ;

Zehir, Ahmet ;

Shah, Ronak H. ;

Benayed, Ryma ;

Syed, Aijazuddin ;

Chandramohan, Raghu ;

Liu, Zhen Yu ;

Won, Helen H. ;

Scott, Sasinya N. ;

Brannon, A. Rose ;

O'Reilly, Catherine ;

Sadowska, Justyna ;

Casanova, Jacklyn ;

Yannes, Angela ;

Hechtman, Jaclyn F. ;

Yao, Jinjuan ;

Song, Wei ;

Ross, Dara S. ;

Oultache, Alifya ;

Dogan, Snjezana ;

Borsu, Laetitia ;

Hameed, Meera ;

Nafa, Khedoudja ;

Arcila, Maria E. ;

Ladanyi, Marc ;

Berger, Michael F. .

JOURNAL OF MOLECULAR DIAGNOSTICS, 2015, 17 (03) :251-264

[8] Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring an ERBB2 S310F Mutation [J].

Chumsri, Saranya ;

Weidler, Jodi ;

Ali, Siraj ;

Balasubramanian, Sohail ;

Wallweber, Gerald ;

DeFazio-Eli, Lisa ;

Chenna, Ahmed ;

Huang, Weidong ;

DeRidder, Angela ;

Goicocheal, Lindsay ;

Perez, Edith A. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (09) :1066-1070

[9] Activating HER2 mutations as emerging targets in multiple solid cancers [J].

Connell, Claire M. ;

Doherty, Gary J. .

ESMO OPEN, 2017, 2 (05)

[10] Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial [J].

Dieras, Veronique ;

Miles, David ;

Verma, Sunil ;

Pegram, Mark ;

Welslau, Manfred ;

Baselga, Jose ;

Krop, Ian E. ;

Blackwell, Kim ;

Hoersch, Silke ;

Xu, Jin ;

Green, Marjorie ;

Gianni, Luca .

LANCET ONCOLOGY, 2017, 18 (06) :732-742

← 1 2 3 4 5 →